Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of sinomenine or medically acceptable salt thereof for preparing drugs for treatment of ischemic necrosis of femoral head

A technology of ischemic necrosis and sinomenine, which is applied in the direction of medical preparations containing active ingredients, drug combinations, antipyretics, etc., can solve problems such as unpredictable curative effects, achieve no toxic side effects, less trauma, and definite curative effect Effect

Inactive Publication Date: 2019-12-06
HUNAN ZHENGQING PHARM GRP CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of osteonecrosis of the femoral head includes surgery to preserve the patient's own femoral head and artificial hip replacement. expected

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of sinomenine or medically acceptable salt thereof for preparing drugs for treatment of ischemic necrosis of femoral head
  • Use of sinomenine or medically acceptable salt thereof for preparing drugs for treatment of ischemic necrosis of femoral head
  • Use of sinomenine or medically acceptable salt thereof for preparing drugs for treatment of ischemic necrosis of femoral head

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Take 2ml of 25mg / ml injection. The injection is made of sinomenine hydrochloride as the active ingredient, disodium edetate, sodium bisulfite, and sterile water for injection. The injection is compatible with 2ml of lidocaine hydrochloride. Weekly acupoint injection, once a day, acupoint injection treatment for 7 days as a course of treatment, after a week of rest, continue to the next course of treatment, 6 courses of treatment. On the basis of acupoint injection treatment, the original electroporation combined with 25mg / ml transdermal absorption agent 2ml was used for transdermal administration. The transdermal absorption agent consisted of sinomenine hydrochloride as the active ingredient and edetate disodium Made of sodium hydrogen and sterile water for injection, once a day, 30 minutes each time, transdermal administration for 30 days is a course of treatment, and the medication cycle is 3 courses of treatment.

Embodiment 2

[0040] Take 2ml of 25mg / ml injection, which is made of sinomenine hydrochloride as the active ingredient, disodium edetate, sodium bisulfite, and sterile water for injection, and the injection is compatible with lidocaine hydrochloride 3ml, in the joint cavity and Acupoint injection around the hip, once a day, acupoint injection treatment for 7 days as a course of treatment, after a week of rest, continue to the next course of treatment, 6 courses of treatment. On the basis of acupoint injection treatment, the original electroporation combined with 25mg / ml transdermal absorption agent 4ml was used for transdermal administration. The transdermal absorption agent consisted of sinomenine hydrochloride as the active ingredient and edetate disodium Made of sodium hydrogen and sterile water for injection, once a day, 30 minutes each time, transdermal administration for 30 days is a course of treatment, and the medication cycle is 3 courses of treatment.

Embodiment 3

[0042]Take 3ml of 25mg / ml injection, which is made of sinomenine hydrochloride as the active ingredient, disodium edetate, sodium bisulfite, and sterilized water for injection. The injection is compatible with 2ml of lidocaine hydrochloride. Acupoint injection around the hip, once a day, acupoint injection treatment for 7 days as a course of treatment, after a week of rest, continue to the next course of treatment, 12 courses of treatment. On the basis of acupoint injection treatment, the original electroporation combined with 25mg / ml transdermal absorption agent 2ml was used for transdermal administration. The transdermal absorption agent consisted of sinomenine hydrochloride as the active ingredient and edetate disodium Made of sodium hydrogen and sterile water for injection, once a day, 30 minutes each time, transdermal administration for 30 days is a course of treatment, and the medication cycle is 6 courses of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses use of sinomenine or medically acceptable salt thereof for preparing drugs for treatment of ischemic necrosis of femoral head. The sinomenine or the medically acceptable salt thereof is used as an active ingredient to be dosed to patients in combination with an injection and a transdermal absorbent. The use has the advantages that the sinomenine or the medically acceptablesalt thereof is used as the active ingredient and matched with an auxiliary agent to prepare the drug fixed-point injection therapy and transdermal drug delivery for the treatment of the ischemic necrosis of the femoral head, definite curative effect is achieved on the patients with the ischemic necrosis of the femoral head, the cystic and necrotic changes of the femoral head can be stopped, partof bone trabecula can be improved, and good effects are still achieved on the aspects of pain relief, improvement of hip joint mobility and the like. The method is small in trauma, good in curative effect, simple in method, no in toxic and side effects and crippling risk, the method is good conservative treatment for the ischemic necrosis of the femoral head, and is worthy of clinical applicationand popularization.

Description

technical field [0001] The invention relates to a new application of a medicine, in particular to the application of sinomenine or a pharmaceutically acceptable salt thereof for preparing a medicine for treating avascular necrosis of the femoral head, and belongs to the field of alkaloid medicine application. Background technique [0002] Avascular necrosis of the femoral head is one of the three major problems in the medical field today, and the etiology is complex. Avascular necrosis of the femoral head is a pathological process in which the blood supply of the femoral head is destroyed due to a variety of causes and the active components of the bone (including bone cells, bone marrow hematopoietic cells and fat cells) die. It can be divided into traumatic and non-traumatic two categories. Traumatic avascular necrosis of the femoral head is mainly seen in hip trauma, such as: femoral neck fracture, femoral head fracture, hip dislocation, acetabular fracture, etc., and nec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/485A61P19/08A61P19/02A61P29/00
CPCA61K31/485A61P19/08A61P19/02A61P29/00
Inventor 尹怡辉彭晓珊陈华李璐璐滕健李燕平仇萍
Owner HUNAN ZHENGQING PHARM GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com